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Abstract
Congenital disorders of glycosylation (CDG) are a group of rare metabolic diseases, due to impaired protein and lipid
glycosylation. In the present study, exome sequencing was used to identify MAN1B1 as the culprit gene in an unsolved CDG-
II patient. Subsequently, 6 additional cases with MAN1B1-CDG were found. All individuals presented slight facial
dysmorphism, psychomotor retardation and truncal obesity. Generally, MAN1B1 is believed to be an ER resident alpha-1,2-
mannosidase acting as a key factor in glycoprotein quality control by targeting misfolded proteins for ER-associated
degradation (ERAD). However, recent studies indicated a Golgi localization of the endogenous MAN1B1, suggesting a more
complex role for MAN1B1 in quality control. We were able to confirm that MAN1B1 is indeed localized to the Golgi complex
instead of the ER. Furthermore, we observed an altered Golgi morphology in all patients’ cells, with marked dilatation and
fragmentation. We hypothesize that part of the phenotype is associated to this Golgi disruption. In conclusion, we linked
mutations in MAN1B1 to a Golgi glycosylation disorder. Additionally, our results support the recent findings on MAN1B1
localization. However, more work is needed to pinpoint the exact function of MAN1B1 in glycoprotein quality control, and
to understand the pathophysiology of its deficiency.
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Introduction
Congenital Disorders of Glycosylation (CDG) are a group of
genetic diseases, due to deficient protein and lipid glycosylation
[1]. To date, over 60 distinct disorders have been described,
comprising a very broad range of phenotypes [2]. However, the
search for the culprit gene in an unsolved CDG case can be very
laborious, due to its heterogeneous clinical presentation and the
extensive list of candidate genes. Over the last few years, massive
parallel sequencing techniques have permitted to identify the
underlying genetic defect in a growing number of diseases. In case
of CDG, exome sequencing led to the discovery of 7 novel
disorders in less than 2 years [3].
N-glycosylation of proteins is a meticulously orchestrated
process occurring in the cytosol, the endoplasmic reticulum (ER)
and the Golgi apparatus. Responsible for the modification of
secreted and transmembrane proteins, N-glycosylation is consid-
ered as one of the most widespread forms of glycosylation. A
prerequisite for export of a protein out of the ER and its further
transport through the secretory pathway is the adaptation of a
native folding state [4]. However, protein folding is inherently
error prone. Therefore, a quality control system has evolved to
ensure that only properly folded proteins reach the plasma
membrane. Glycoproteins unable to acquire a correct conforma-
tion will be recognized as terminally misfolded and marked for
degradation by demannosylation of their glycan moiety.
The a(1,2)-mannosidase, MAN1B1, catalyzes the removal of the
terminal mannose residue from the middle branch of Man9-
GlcNAc2, hence generating a degradation signal corresponding to
Man8GlcNAc2 isomer B [5]. Initially, MAN1B1 was predicted to
function as an ER resident protein, based on the localization of its
yeast orthologue Mns1p [6]. Also the overexpressed recombinant
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human orthologue was found to reside within the ER [7].
However, recent studies indicate that the endogenous MAN1B1
localizes to the Golgi apparatus of mammalian cells, implying that
quality control is not confined to the ER, but stretches throughout
the secretory pathway [8]. In this new model, MAN1B1 functions
not only as a checkpoint for misfolded proteins escaping the ER,
but also as a lectin retrieving these proteins back to the ER prior to
their degradation by the 26S proteasome.
Interestingly, mutations in MAN1B1 have been recently
associated with non-syndromic autosomal recessive intellectual
disability (NS-ARID) [9–10]. However, in the present study we
show that MAN1B1 deficiency is associated with N-glycosylation
disorders and causes a CDG-II syndrome. In addition, our
findings suggest that MAN1B1 plays a role in protein quality
control at the level of the Golgi apparatus.
Results
Whole exome sequencing and gene identification
To identify the causative gene in an unsolved CDG-II case, we
performed whole exome sequencing by using the SeqCap EZ
Human Exome Library v2.0 and the Illumina HiSeq2000. A total
number of 29,518,319 reads were retrieved. 89% of the reads
generated passed CASAVA quality filters, were unique, and
mapped to the reference genome. The mean target coverage was
56, with 83% of the target covered at least 20-fold. Quality
filtering led to a total of 29,437 variants, of those 11,026 were
nonsynonymous. 702 variants had a frequency lower than 1% in
the 1000 Genomes project. 8 homozygous variants and 132
compound heterozygous variants fitted with a recessive disease
model. From this 140 variants, 4 were retained based on a
Polyphen-2 score higher than 0.8. Out of this list, 2 were
homozygous and 2 compound heterozygous (Table 1). The variant
detected in MAN1B1 (MIM 604346) encoded the c.1225T.C
(p.S409P) mutation in a homozygous state. The sequencing depth
of this variant was 22 reads. On the basis of the described function
of MAN1B1, this gene was the best candidate from the list. Using
Sanger sequencing, we confirmed the presence of the homozygous
missense mutation in exon 8 of MAN1B1. This serine residue is
highly conserved. The software tools SIFT, PolyPhen-2 and
Project HOPE predicted the mutation to be damaging (Figure S1,
Figure S2). The serine 409 is located within an alpha helix of the
protein. We hypothesize that the mutation would impair
MAN1B1 function by either breaking or kinking this helix.
Sequencing of MAN1B1 in a cohort of individuals with unsolved
CDG-II allowed us to identify 6 other cases with MAN1B1
mutations. Case 2 is compound heterozygous for the same
missense mutation c.1225T.C (p.S409P) in exon 8, and the
nonsense mutation c.172G.T (pE58X) in exon 1. Case 3 was
found to carry the homozygous missense mutation c.1000C.T
(p.R334C) in exon 7 (Figure S1). Cases 4.1 and 4.2 are
homozygous for the same missense mutation as case 3, namely
p.R334C. The arginine residue at position 334 is located within an
alpha helix of the protein and strictly conserved (Figure S2).
Furthermore it is localized at the active site pocket of the protein,
where it interacts with the substrate via hydrogen bonding. The
conversion to a cysteine might then alter the electrostatic
interactions necessary for binding of the substrate in the active
site. Case 5 was found to carry a homozygous 2 bp deletion
c.1833_1834delAG (p.T611del), causing a frameshift that results
in an alternative protein, missing many of the residues required for
substrate recognition. Case 6 carried a heterozygous 4 bp deletion
in intron 9 (c.1445+2delTGAG). Sequencing of full MAN1B1
cDNA did not only confirm splicing of exon 9 due to the 4 bp
deletion, but also revealed a heterozygous loss of exon 4. To prove
that this event on cDNA was due to a deletion of exon 4, a long
template PCR on genomic DNA stretching from exon 2 to exon 5
was performed. The PCR product revealed a shorter fragment of
approximately 3,000 bp instead of the estimated 10,000 bp,
confirming the presence of a heterozygous deletion of exon 4
(data not shown). Further sequencing of the boundaries showed a
deletion of 6,453 bp (c.465+1460_620+527del). The 4 bp deletion
in intron 9 was located on the maternal allele. The deletion of
exon 4 occurred de novo on the paternal allele (Figure S1F).
Clinical presentation
The index case (P1, Figure 1A) is a 16 years old girl of
Portuguese origin. Head circumference and length at birth were
situated at percentile 97. The girl presented with psychomotor
retardation and hypotonia. There was slight facial dysmorphism.
A brain MRI performed at the age of 7, showed cerebellar
hypoplasia with vermian atrophy. To date, she presents severe
psychomotor retardation and obesity.
Case 2 (P2, Figure 1B, 1C) is a 12 years old boy. He was born as
the first child of healthy, non-consanguineous parents of Portu-
guese origin. Developmental delay was noted at the age of 18
months. He presented with hypotonia and slight facial dysmor-
phism. Fingers were long and thin. Brain MRI was normal. To
date, he displays moderate mental retardation (IQ 43) and obesity
(BMI..P97). Periods of auto-aggressive behaviour and repetitive
movements occur.
Case 3 (P3, Figure 1D) is an 11 years old girl of Turkish origin.
She presented with delayed motor development at the age of 3
years. Brain MRI was normal. She showed slight facial dysmor-
phism, hypermobility of the joints and skin laxity. To date she
presents with mild mental retardation, short stature (length,P3),
truncular obesity (weight at P50) and macrocephaly (head
circumference at P97).
Case 4.1 (P4.1, Figure 1E) and case 4.2 (P4.2, Figure 1F) are
siblings of Turkish origin. Parents are consanguineous (first
cousins). Case 4.1 is a 24 years old woman. She came under
medical attention because of mild psychomotor retardation and
hypotonia. Brain MRI was normal. She showed slight facial
dysmorphism, hypermobility of the joints and skin laxity. She
presented an important scoliosis, which was corrected by surgery
at the age of 18. To date, she presents mild mental retardation (IQ
62) and truncular obesity.
Author Summary
Glycosylation concerns the synthesis of sugar chains, their
addition onto proteins and/or lipids, and their subsequent
modifications. The resulting glycoproteins serve many
critical roles in metabolism. The importance of this
pathway is illustrated by a group of diseases called
Congenital Disorders of Glycosylation (CDG). To date, over
60 distinct disorders have been described. In the present
study, we demonstrated that mutations in MAN1B1, a gene
formerly linked to non-syndromic intellectual disability,
cause CDG. We described 7 patients with similar clinical
features (developmental delay, intellectual disability, facial
dysmorphism and obesity), defining MAN1B1-CDG as a
syndrome. Furthermore, we confirmed that the MAN1B1
protein is localized into the Golgi apparatus instead of the
endoplasmic reticulum, where it was assumed to reside for
many years. Moreover, we showed that mutations in
MAN1B1 lead to alterations of the Golgi structure.
MAN1B1-CDG: A New CDG-II
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Case 4.2 is a 18 years old man. He presented with psychomotor
retardation and hypotonia. Brain MRI was normal. There was
only slight facial dysmorphism and skin laxity. To date, he presents
mild mental retardation (IQ 69) and obesity.
Case 5 (P5, Figure 1G, 1H) is a 13 years old boy. He was born at
term as the first child of healthy, non-consanguineous parents of
Belgian origin. He presented with hypotonia and slight dysmorphic
features. Fingers were long and thin. Hypermobility of the joints and
skin laxity were noticed, as well as a pectus excavatum. Dilatation of
the aortic root was seen on cardiac ultrasound. BrainMRI performed
at the age of 3 months was normal. At the age of 5 years he was
diagnosed with epilepsy (absences). To date, he presents mild mental
retardation and is able to use simple language. Growth and weight
evolution are normal, though he displays truncular fat accumulation.
Table 1. Overview of candidate variants identified by exome sequencing.
Gene symbol Gene name Transcript Nucleotide change Protein change
Mutation
type
Predicted
zygosity Chromosome
MAN1B1 Mannosidase, alpha,
class 1B, member 1
NM_016219 c.1225T.C p.S409P Missense Homo 9
WDR85 WD repeat domain 85 NM_138778 c.824C.T p.P275L Missense Homo 9
CRIM1 Cysteine rich
transmembrane BMP
regulator 1
NM_016441 c.618A.C p.L206F Missense Het 2
CRIM1 Cysteine rich
transmembrane BMP
regulator 1
NM_016441 c.2104A.C p.T702P Missense Het 2
For the analysis of candidate variants, variants from the single nucleotide polymorphism database (dbSNP) and with a higher frequency than 1% in the 1000 Genomes
project were excluded. Based on recessive inheritance, a subsequent prioritization was applied using the following criteria: a minimum of 80% variant reads for potential
homozygous and between 20 and 60% for compound heterozygous variants.
doi:10.1371/journal.pgen.1003989.t001
Figure 1. Clinical features of the seven cases. Clinical features of P1 at the age of 7 years (A), P2 at the age of 10 years (B, C), P3 at the age 3.5
years (D), P4.1 at the age of 18 years (E), P4.2 at the age of 12 years (F), P5 at the age of 13 years (G, H) and P6 at the age of 5 years (I, J). Note the facial
dysmorphism, i.e. hypertelorism with downslanting palpebral fissures (A, D, E, F, G), large, low set ears (A, B, C, D, E, F, G, J), thin upper lip with
hypoplastic nasolabial fold (A, B, D, E, F, G, I), tubular nose in P1, P4.1 and P4.2 (A, E, F) and a depressed nasal bridge in patients P2, P3, P5 and P6 (B, D,
G, I). Note the truncular obesity (C, E, F, H) and the widely spaced, inverted nipples (B, F, H). Note the pectus excavatum in P5 (H).
doi:10.1371/journal.pgen.1003989.g001
MAN1B1-CDG: A New CDG-II
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Case 6 (P6, Figure 1I, 1J) is a 12 years old girl. She was born as
the first child of healthy, non-consanguineous parents of Belgian
origin. Reduced fetal movements were observed during pregnan-
cy. After birth, she was diagnosed to have a muscular ventricular
septum defect (VSD). Spontaneous closure occurred. Develop-
mental delay was notified at the age of 18 months. She displayed
hypotonia and a delay in motor development. There was slight
facial dysmorphism, hypermobility of the joints, and skin laxity.
Fingers were long and thin. At the age of 5, she was diagnosed
with an autism spectrum disorder and mild mental retardation (IQ
52). Brain MRI showed multiple, small white matter lesions.
Rapid bone maturation and early puberty occurred because of
overweight.
Clinical features of all patients are furthermore compared in
Table 2.
Capillary zone electrophoresis (CZE) of serum showed a type 2
transferrin pattern with an increase of trisialotransferrin (repre-
senting 31 to 41% of the transferrin isoforms, normal range: 1–
8%) in all affected cases (Table S1). Isoelectrofocusing of serum
transferrin (sTF-IEF) confirmed these results (Figure 2). This
categorized them as CDG-II.
Structural analysis of N-glycans and Golgi morphology
The type 2 sTF-IEF pattern pointed to an N-glycan remodelling
defect. Therefore, we investigated the Golgi glycosylation in more
detail and determined the structures of the N-linked glycans on serum
glycoproteins from controls and affected cases by using mass
spectrometry (Figure 3). In MAN1B1-deficient individuals (P2, P5),
we observed the accumulation of the hybrid-type glycan structure
NeuAc1Hex6HexNAc3 (m/z 2,390), present together with the
corresponding fucosylated NeuAc1Hex6HexNAc3dHex1 (m/z
2,564). We also observed a significant increase of the sialylated
NeuAc1Hex5HexNAc3 (m/z 2,186) with respect to the control. This
glycan also appeared to be present together with the corresponding
fucosylated one (NeuAc1Hex5HexNAc3dHex1; m/z 2,360) which
was not present in the control. In MAN1B1-CDG cases, there was
also a marked increase of Hex6HexNAc2 (m/z 1,783), but no
significant variations of Hex5HexNAc2 (m/z 1,579).
These results were confirmed in a second group of MAN1B1-
CDG cases (P1, P4.1, P4.2 and P6) that were analysed
independently (Figure S3). We noticed the presence of hybrid-
type glycan structures NeuAc1Hex5HexNAc3 and NeuAc1Hex6-
HexNAc3. These glycans appeared to be present together with the
corresponding fucosylated NeuAc1Hex5HexNAc3dHex1 and
NeuAc1Hex6HexNAc3dHex1, respectively. These four species
were not detected in controls.
Because the N-glycans abnormalities suggested a Golgi glyco-
sylation defect, Golgi morphology was investigated. Staining with
the Golgi markers TGN46 and GM130 detected significant
alterations in Golgi morphology in fibroblasts of all affected cases,
with marked dilatation and fragmentation (Figure 4).
Table 2. Clinical features of patients with MAN1B1 deficiency.
Clinical features P1 P2 P3 P4.1 P4.2 P5 P6
Current age (yrs) 16 12 11 24 18 13 12
Gender F M F F M M F
Ethnicity Portuguese Portuguese Turkish Turkish Turkish Belgian Belgian
Mental retardation severe moderate mild mild mild mild mild
Delayed motor development + + + + + + +
Behavioral problems 2 + 2 NA NA 2 +
Autism 2 2 2 NA NA 2 +
Seizures 2 2 2 2 2 + 2
Hypotonia + + + + + + +
Cerebellar hypoplasia + 2 2 2 2 2 2
Hypertelorism + 2 + + + + +
Downslanting palpebral fissures + +/2 + + + + +
Large, low-set ears + + + + + + +
Thin upper lip + + + + + + +/2
Hypoplastic nasolabial fold + + + 2 2 + +
Truncal obesity + + + + + + +
Inverted nipples 2 2 + 2 + + +
Joint hypermobility 2 2 + + 2 + +
Skin laxity 2 2 + + + + +
The presence (+) or absence (2) of each feature is reported for each individual. The following abbreviations are used: NA, not available; yrs: years; F: female; M: male.
doi:10.1371/journal.pgen.1003989.t002
Figure 2. IEF profiles of serum transferrin. Isoelectrofocusing
pattern of serum transferrin in MAN1B1-deficient individuals and a
control. 2, 4 and 6 indicate disialo-, tetrasialo-, and hexasialotransferrin
isoforms, respectively. The asterisk mark represents the trisialotransfer-
rin isoform.
doi:10.1371/journal.pgen.1003989.g002
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Functional analysis of MAN1B1 mutations
We used quantitative real-time PCR (qPCR) to investigate the
effects of the mutations on MAN1B1 expression by comparing
MAN1B1 cDNA levels amplified from mRNA isolated from control
and MAN1B1-deficient fibroblasts, cultured in the presence or
absence of the translation inhibitor puromycin. Compared to
controls, most of the MAN1B1-deficient individuals presented an
expression increased 1.22 to 1.49 fold compared to the wild-type
MAN1B1 transcript. Case 2, who harbours the nonsense mutation
p.E58X, showed an expected reduced expression level of 40%
compared to control. Case 6 showed an expression level of 2%
compared to control, likely because the deletions on both alleles lead
to instability of the transcript (Figure 5A, left panel). Culturing control
and MAN1B1-deficient fibroblasts in presence of puromycin did not
markedly alter these expression levels (Figure 5A, right panel).
To further investigate the effects of the mutations onMAN1B1, we
performed immunoblotting using control and MAN1B1-deficient
fibroblasts. As shown in Figure 5B, an extremely low level of
endogenous MAN1B1 was detected in affected cases. The steady-
state level of MAN1B1 in P3 was reduced to 24%, suggesting that the
protein was slightly more stable than in the other affected individuals.
We then compared the subcellular localization of MAN1B1 in
control and MAN1B1-deficient fibroblasts by confocal microsco-
py. In accordance with the data recently published by Pan and
coworkers [8], the endogenous MAN1B1 showed a clear
perinuclear Golgi-like distribution (Figure 5C and Figure S4, first
row) rather than a typical diffuse ER localization. As expected
from the western blot analysis, some of the MAN1B1-deficient
individuals did not show any staining. A faint Golgi localization
could be seen in some of the affected cases, despite the largely
predominant Golgi staining for giantin (Figure 5C, Figure S4).
Subcellular MAN1B1 localization
As mentioned above, MAN1B1 displayed a perinuclear Golgi
distribution. Double labelling of control cells with MAN1B1 and
the rough ER marker PDI showed a clear separation of the two
proteins (Figure 6A). A similar pattern was obtained regarding the
distribution of both MAN1B1 and the ER protein GRP78,
suggesting that the mannosidase was located apart from the ER
compartment (data not shown). In order to gain insights into the
precise MAN1B1 subcellular localization, we examined its
distribution in the Golgi and the ER-Golgi intermediate
compartment (ERGIC). MAN1B1 showed a high level of
colocalization with both the trans-Golgi marker GPP130 and the
cis-Golgi marker giantin. Only weak colocalization with the
ERGIC marker ERGIC-53 was noted (Figure 6A). The intensity
of the different protein markers was plotted against the distance,
using the RGB profiler plugin from Image J (Figure 6B). The level
of colocalization was quantified as a percentage of the area
occupied by the colocalized spots from the total labelled spots,
based on Pearson’s coefficient. These results showed a much
higher degree of colocalization for MAN1B1 versus GPP130
(80%63) or giantin (84%62), than for MAN1B1 versus ERGIC-
53 (41%64), which is consistent with the qualitative data. These
results strongly suggest that MAN1B1 is widely distributed within
the Golgi apparatus and is hardly or not detectable in the ER.
MAN1B1 deficient fibroblasts present a delay of trimming
from Man9GlcNAc2 to Man8GlcNAc2
The impact of MAN1B1 on Golgi glycosylation was studied in
MAN1B1-deficient fibroblasts. The cells of individuals mutated in
MAN1B1 were further investigated by metabolic labelling.
MAN1B1 is reportedly known to be the key enzyme responsible
Figure 3. MAN1B1-deficient individuals are deficient in protein N-glycosylation. MALDI-TOF spectra of the permethylated N-glycans from
sera of control and MAN1B1-deficient individuals. Respective m/z values of N-glycans structures accumulating in MAN1B1-deficient cells are displayed
in red. The symbols representing sugar residues are as follows: closed square, N-acetylglucosamine; closed circle: mannose; open circle, galactose;
closed diamond, sialic acid; and closed triangle, fucose. Linkages between sugar residues have been removed for simplicity.
doi:10.1371/journal.pgen.1003989.g003
Figure 4. MAN1B1-deficient fibroblasts present alterations in Golgi structure. Golgi localization of GM130 (red) and TGN46 (green) in
control and MAN1B1-deficient fibroblasts. Cells were fixed, double-labelled with antibodies against GM130 and TGN46, and analysed by confocal
laser scanning microscopy. Scale bar represents 10 mm.
doi:10.1371/journal.pgen.1003989.g004
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for the trimming of Man9GlcNac2 species to Man8GlcNAc2
species [5]. To address the potential deleterious effect of the
mutations on MAN1B1 function, a structural analysis of the N-
linked protein glycans was performed. Therefore, cells were pulse-
labelled with 2-[3H] mannose and chased for 2 h. In healthy
controls as well as in MAN1B1-deficient cells, Man8GlcNAc2,
Man9GlcNAc2 and Glc1Man9GlcNAc2 structures were found
after the pulse period (Figure 7A, 7B and Figure S5A). As
expected, when the control glycoproteins were chased for 2 hours,
an increase of Man8GlcNAc2 species was observed indicating that
the Man9GlcNAc2 species can serve as substrate for further
trimming by ER/Golgi mannosidases. In contrast, only a slight
Figure 5. Functional analyses of MAN1B1 mutations. (A) Quantification of the MAN1B1 transcript in controls and affected individuals by qPCR
without (left panel) and with (right panel) puromycin. MAN1B1 expression was normalized to the expression of the house-keeping gene HPRT. Values
plotted with a wild-type control untreated with puromycin are set to 1. The depicted values are the mean 6 SEM of at least three independent
experiments. (B) Steady-state levels of the expression of MAN1B1 in control (C) and MAN1B1-deficient (P) fibroblasts. Whole-cell extracts were
analysed by immunoblotting using anti-MAN1B1 antibodies. Thirty micrograms of total cell extracts were loaded into each lane and anti-b-actin
antibodies were used as a loading control. Quantifications represent the mean value of three independent loadings of three independent samples.
(C) Intracellular distribution of MAN1B1 in control and MAN1B1-deficient fibroblasts. Fibroblasts were double-labelled with antibodies against
MAN1B1 (green) and the Golgi marker giantin (red), then fixed and processed for analysis by confocal laser scanning microscopy. Images were
collected under identical settings. Depicted are the zoomed images. The independent panels are presented in Figure S4.
doi:10.1371/journal.pgen.1003989.g005
MAN1B1-CDG: A New CDG-II
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increase of Man8GlcNAc2 species was seen in MAN1B1-deficient
cells (Figure S5B). The processing efficacy from Man9 to Man8
was hence estimated for both healthy controls and MAN1B1-
deficient cells. Figure 7C shows that this processing efficacy was
estimated to 100%66.9 in control cells but ranged between
40.1%65.9 to 43.6%62.2 for MAN1B1-deficient cells. Surpris-
ingly, this value was much lower for P1 cells, with an average
efficacy of 17.7%63.8. These results strongly suggest that in
MAN1B1-deficient cells, a delay in the trimming of Man9-
GlcNAc2 species occurs. For statistical relevance, we compared
the mean processing efficacy of the 3 control cell lines to the mean
processing efficacy of all 4 MAN1B1-deficient cell lines
(Figure 7D). We conclude that the deficiency of processing from
Man9GlcNAc2 species to Man8GlcNAc2 species is not complete,
since this value remains of 36.1%612.8 (p value,0.001) in cells of
affected individuals (Figure 7D). This is likely due to the action of
other ER/Golgi mannosidases or alpha-mannosidase like proteins
such as EDEM proteins, which enable trimming of Man9 to Man8
species in mammalian cells.
Discussion
MAN1B1 encodes the endoplasmic reticulum mannosyl-
oligosaccharide 1,2-alpha-mannosidase (ERManI), which cleaves
the terminal mannose from the middle branch of Man9GlcNAc2,
then producing Man8GlcNAc2 isomer B. It is believed to play a
key role in glycoprotein quality control, by targeting terminally
misfolded proteins for ERAD. The capacity to distinguish between
terminally misfolded proteins and properly folded intermediates as
appropriate ERAD substrates is indeed known to be one of the
Figure 6. Subcellular localisation of MAN1B1. (A) Indirect double immunofluorescence staining of control and MAN1B1-deficient fibroblasts.
The cells were double-labelled with antibodies against MAN1B1 and with antibodies against either the Golgi markers GPP130 and giantin, the ER-
Golgi intermediate compartment (ERGIC) marker ERGIC-53, or the ER marker PDI. The cells were then examined by confocal laser scanning
microscopy. Images were collected under identical settings. Scale bar represents 10 mm. (B) Confocal linescan analysis of the distribution of MAN1B1.
The pixel intensity (vertical axis) of MAN1B1 (green) and PDI, ERGIC-53, giantin and GPP130 (from top to bottom, red) was hence measured along a
vector drawn perpendicular across the Golgi stack and plotted versus distance (horizontal axis), using the RGB profiler plugin from Image J.
doi:10.1371/journal.pgen.1003989.g006
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early steps in protein quality control. Several studies in both yeast
and mammalian cells already provided evidence that the removal
of terminal mannose residues from asparagine-linked Man9-
GlcNAc2 glycan structures generates a signal for ERAD [11].
However, the exact function of MAN1B1 is still unclear.
In the present study, we definitely link mutations in MAN1B1 to
pathology that presents as a deficiency of glycosylation. The first
patients with MAN1B1 deficiency were detected in a study on NS-
ARID [9]. We identified MAN1B1 mutations in 7 cases with
unsolved CDG-II. All patients presented a certain degree of
intellectual disability, but also had facial dysmorphism and obesity.
Furthermore, some of them displayed joint hypermobility and skin
laxity. Dysmorphic features were similar for all cases, i.e.
downslanting palpebral fissures, hypertelorism, large low set ears,
a hypoplastic nasolabial fold and a thin upper lip. These clinical
characteristics correspond to the phenotype of the formerly
published patients, although the author assigned the dysmorphism
to family traits rather than to the disease [9]. Overall, individuals
with MAN1B1-CDG present a mild phenotype, which is in
concordance with studies in Saccharomyces cerevisiae, since the yeast
orthologueMNS1 is not essential for growth [12]. The mild disease
resulting from MAN1B1 deficiency however contrasts with
another defect of N-glycan trimming, which is caused by
mutations in the glucosidase I (MOGS) gene. A single case of
MOGS deficiency has been reported so far, characterized by
dysmorphism and hypotonia, leading to the death of the affected
infant [13]. We believe that MAN1B1 deficiency belongs to the
relatively frequent CDG. In our cohort of solved CDG-II cases,
the occurrence of MAN1B1-CDG is indeed over 25%, more
frequent than TMEM165-CDG, COG5-CDG or COG7-CDG
(14% respectively). From the overall number of solved CDG cases
(CDG-I plus CDG-II) in our database, MAN1B1-CDG is the fifth
most frequently encountered CDG type (1.9%), right behind
SRD5A3-CDG (2.6%) or PMI-CDG (2.8%). PMM2-CDG and
ALG6-CDG are the most frequent (69.9% and 8.5%, respective-
ly). The genetic results were supported by a significant decrease in
Figure 7. HPLC analysis of N-linked oligosaccharides from control and patient’s fibroblasts reveal a delay of trimming from
Man9GlcNAc2 to Man8GlcNAc2 in MAN1B1-deficient patients. Protein N-linked oligosaccharides of two different control (A) and one
MAN1B1-deficient individuals (P2, B) were separated by HPLC after the pulse period (left panels) and 2 hours of chase (right panels). Depicted for
both controls and P2 are two representative chromatograms from two independent experiments, with one set of experiments presented in the upper
panel, and a second one in the lower panel. Symbols: M8, M9 indicate oligosaccharide species with 8 or 9 mannose residues and possessing two
GlcNAc resides at their reducing ends. G1M9 indicates oligosaccharide species with 9 mannose and 1 Glc residues and possessing two GlcNAc
residues at their reducing ends. (C) Relative peak areas of M8, M9, and G1M9 were quantified and the results expressed as the percentage of
processing efficiency to M8. In the calculation, the trimming efficiency from M9 to M8, which corresponds to the difference between the percentage
of M8 at T0 h and T2 h, was considered as 100%. The depicted values are the mean6 SEM of independent experiments. (D) Comparison of the mean
processing efficacy of the three control cell lines (C) to the mean processing efficacy of all four MAN1B1-deficient cell lines (P). Data were analysed by
using Student’s t test. *** indicates a p value,0.001.
doi:10.1371/journal.pgen.1003989.g007
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steady-state levels of the MAN1B1 protein. Enzymatic activity was
measured indirectly by pulse-chase experiments with 2-[3H]
mannose, which showed a significant delay in the trimming of
Man9GlcNAc2 to Man8GlcNAc2. The trimming efficiency in
MAN1B1-deficient cells was still up to 36%. This activity is likely
due to the action of other ER/Golgi class I mannosidases or alpha-
mannosidase-like proteins such as EDEM proteins, cleaving the
terminal mannose residue at a lower rate.
Former studies localized the overexpressed recombinant
MAN1B1 protein within the ER or the ERGIC. The S. cerevisiae
homologue of MAN1B1, Mns1p, was originally demonstrated to
function as an ER-resident protein [14]. The humanMAN1B1 was
then identified and cloned on the basis of its close sequence
homology with MNS1 and was therefore predicted to localize and
function in the ER [7] [15], despite a more than 50% sequence
homology with Golgi a(1,2)-mannosidases IA, IB an IC [15]. We
could clearly demonstrate that the endogenous MAN1B1 shows a
Golgi distribution in primary skin fibroblasts. Further determina-
tion of its localization within the organelle revealed an equal
distribution throughout the Golgi apparatus. This result confirms
the initial observation of Sifers and coworkers, who used a panel of
highly specific mAbs to demonstrate that human endogenous
ERManI is O-glycosylated and localized in the Golgi apparatus
[8]. As expected, only a faint or even no Golgi localization could
be seen in MAN1B1-deficient cells.
One can wonder why the MAN1B1 protein, which is assumed
to play a pivotal role in ERAD substrate generation, is physically
separated from the ER. Traditionally, MAN1B1 was believed to
function as a molecular clock in ER quality control. It was
speculated that the slow processing activity of MAN1B1 deter-
mined the time needed for a protein to acquire its native folding
state. In case of a terminally misfolded protein, futile folding cycles
would provide MAN1B1 prolonged access to the glycan, resulting
in its demannosylation and thereby marking the protein for
proteasomal degradation [16]. However, recent findings indicate
that the quality control system is not confined to the ER but
stretches throughout the secretory pathway. In this model,
MAN1B1 operates as a checkpoint within the Golgi apparatus,
recycling misfolded proteins that escaped ERAD back to the ER,
by interacting with the COP-I machinery. It is assumed that
demannosylation of the glycan moiety will prevent the recycled
protein from reentering the folding cycle after its retrieval to the
ER. Instead, its degradation signal will be recognized by ER
resident lectins, leading to proteasome mediated disposal of the
misfolded protein [8].
How does MAN1B1 deficiency leads to disease? The purpose of
quality control is to minimize the level and toxicity of misfolded
proteins within the cell. So, failure of a checkpoint to recognize
ERAD substrates might have serious repercussions on cell
function. However, patients with MAN1B1-CDG present only a
mild phenotype. Hence, one could assume that additional
checkpoints exist in the Golgi apparatus. This hypothesis is
supported by the observation that other Golgi a(1,2)-mannosidases
were shown to be involved in glycoprotein quality control. In case
of MAN1B1 deficiency, these Golgi mannosidases might be
recruited for post-ER surveillance at the expense of their normal
processing activity, leading to a delay in the trafficking of
glycoproteins through the secretory pathway. If so, a relative
accumulation of glycoproteins will occur within the Golgi
apparatus prior to their impaired secretion. Storage of proteins
will then activate a stress response increasing the capacity of the
Golgi cisternae. The fact that MAN1B1 deficient cells display an
altered Golgi morphology, characterized by dilatation and
fragmentation of the cisternae, could support this hypothesis.
However, this suggestion of a Golgi storage disease is in conflict
with the model raised by Pan and coworkers, rather implying an
increased secretion of misfolded glycoproteins in MAN1B1-
depleted cells [8].
Furthermore, we believe that part of the phenotype might be
explained by these Golgi abnormalities. First of all, disruption of
Golgi morphology could explain the glycosylation deficiency
observed in MAN1B1-deficient patients, by affecting the stability
of key proteins responsible for the creation of the microenviron-
ment necessary for proper Golgi glycosylation. Next, some of the
observed clinical features (skin laxity, joint hypermobility) are also
described in patients with COG5-, COG7- and ATP6VOA2-
CDG. Interestingly, MAN1B1-deficient cells, as well as
ATP6V0A2- and COG-deficient cells, show an altered Golgi
morphology [17–18]. Furthermore, impaired secretion and
intracellular retention of tropoelastin were already proven to
result in skin laxity and joint hypermobility in patients with
ATP6V0A2-CDG, implying that a similar mechanism could cause
skin laxity in MAN1B1-deficient patients [19]. Finally, since the
secretory pathway plays also an important role in neurotransmis-
sion and endocrine regulation, one can hypothesize that impaired
protein secretion underlies the intellectual disability and obesity in
our patients.
In conclusion, we have identified MAN1B1 deficiency as a
relatively frequent CDG-II, since the occurrence of MAN1B1-
CDG is over 25% in our cohort of unsolved CDG-II cases.
Overall, the clinical picture is mild, comprising not only
intellectual disability, but also truncal obesity and facial dysmor-
phism, hence defining MAN1B1-CDG as a syndrome. Further-
more, our results confirm that MAN1B1 is indeed localized to the
Golgi apparatus. We hypothesize that part of the phenotype is
linked to the disruption of Golgi morphology. Though, more work
is needed to pinpoint the exact function of MAN1B1 in
glycoprotein quality control and to understand the pathophysiol-
ogy of its deficiency.
Materials and Methods
Ethics statement
Research on patients’ cells was prospectively reviewed and
approved by the Ethical Committee of the University Hospital of
Leuven. PLOS consent forms were obtained for publication of
clinical pictures.
Capillary zone electrophoresis and isoelectric focusing of
serum transferrin
Capillary zone electrophoresis (CZE) and isoelectric focusing of
serum transferrin (sTF-IEF) were performed as previously
described [20].
Patients and cells
Primary fibroblasts from patients and controls were grown from
a skin biopsy and cultured in Dulbecco’s modified Eagle medium
DMEM/F12 (Life Technologies) supplemented with 10% fetal
bovine serum (Clone III, HyClones) at 37uC under 5% CO2.
Exome sequencing
For the index case, mutation analysis was achieved by whole
exome sequencing. Genomic DNA was sheared by sonication,
platform-specific adaptors were ligated, and the resulting frag-
ments were size selected. The library was captured using the
SeqCap EZ Human Exome Library v2.0 (Roche NimbleGen), and
26 76 bp paired-end reads were generated on a HiSeq2000
(Illumina). Reads that did not pass Illumina’s standard filters were
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removed prior to alignment. Remaining reads were aligned to the
reference human genome (hg19), using the CASAVA pipeline.
Quality filtering was applied by excluding variants found in less
than 5 reads and variants detected in less than 15% variant reads.
Synonymous variants were excluded. To retrieve the quality-
filtered private variants, those with a higher frequency than 1% in
the 1000 Genomes project were excluded. Based on recessive
inheritance, a subsequent prioritization was applied using the
following criteria: a minimum of 80% variant reads for potential
homozygous variants and between 20 and 60% for compound
heterozygous variants. Variants with a Polyphen-2 score of less
than 0.8 were filtered out.
Sanger sequencing
Total RNA was isolated from the primary fibroblasts of the
patient and control cells using the RNeasy Kit (Qiagen). The
amount of extracted RNA was quantified using a NanoDrop
spectrophotometer (Thermo Scientifics) and the purity of RNA
was checked by the ratio of the absorbance at 260 and 280 nm.
2 mg of purified total RNA was then subjected to reverse
transcription with the First-Strand cDNA synthesis Kit (GE
Healthcare) following the manufacturer’s instructions. For PCRs,
cDNAs obtained after reverse transcription were diluted 1:5.
Genomic DNA was extracted from white blood cells or
fibroblasts from the patients and controls. Primers (available on
demand) were designed to amplify the different exons of the
MAN1B1 gene (GenBank accession number NM_016219.4),
including at least 50 bp of the flanking intronic regions.
Consecutive primers within intron 3 and intron 4 were designed
to find deletion breakpoints. Standard cDNA- and gDNA-based
PCR reactions were based on 1 ml DNA in a total volume of 25 ml,
0.2 ml Platinum Taq polymerase (Invitrogen). Standard reaction
conditions were 3 min at 95uC, then 10 cycles of 30 sec at 95uC,
30 sec at 65uC (21uC each cycle), 2 min at 72uC, followed by 25
cycles of 30 sec at 95uC, 30 sec at 55uC and 2 min at 72uC. The
reaction was finished by an incubation of 5 min at 72uC.
A long template PCR stretching from exon 2 to exon 5 was
performed using the Expand Long Template PCR System (Roche
Applied Science). The PCR reaction was based on 4 ml DNA in a
total volume of 50 ml, 0.75 ml Expand Long Template Enzyme
Mix, 5 ml of Buffer 2, a final 300 nM concentration of each primer
and a final 500 mM concentration of dNTPs. Reaction conditions
were 2 min at 95uC, then 10 cycles of 10 sec at 95uC, 30 sec at
65uC, 8 min at 68uC, followed by 25 cycles of 15 sec at 94uC,
30 sec at 65uC and 8 min (+20 sec each cycle) at 68uC. The
reaction was completed with a final elongation of 7 min at 68uC.
For the sequencing of the resulting PCR product, the BigDye
Terminator Ready reaction cycle sequencing kit v.3.1 (Applied
Biosystems) was used. Analysis of the results was performed on an
ABI3100 Avant (Applied Biosystems).
Mass spectrometric analysis of N-linked glycans released
from total plasma proteins
The glycans from total plasma N-glycoproteins were released as
previously described [21–22]. Analysis of N-linked glycans on
plasma glycoproteins was carried out by matrix-assisted laser
desorption ionization time-of-flight mass spectrometry (Ciphergen)
essentially as described for MALDI-TOF-MS, and performed in a
positive linear ion mode [21]. The reference samples were
anonymous plasma samples from patients without CDG and
without a lysosomal storage disease. For cases P1, P4.1, P4.2 and
P6, the lab of P. Mills and colleagues performed the analysis. For
cases P2, P3 and P5, the lab of L. Sturiale and colleagues
performed the analysis.
Antibodies
Anti-MAN1B1 monoclonal antibodies used for indirect immu-
nofluorescence were kindly provided by the lab of Richard N.
Sifers and colleagues (Baylor College of Medicine, Houston, USA).
Monoclonal anti-MAN1B1 antibodies used for western blotting
were from Novus Biologicals. Polyclonal antibodies anti-GPP130
and anti-Giantin were purchased from Covance, polyclonal
antibodies anti-PDI from Cell Signalling, polyclonal antibodies
anti-ERGIC53 from Sigma-Aldrich and polyclonal anti-GRP78
BiP antibodies from Abcam.
Immunoblotting
30 mg of proteins were analysed by SDS-PAGE and immuno-
blotted onto Hybond-ECL nitrocellulose membrane (Amersham
Biosciences UK limited), with the indicated antibodies. Cells were
rinsed twice with ice-cold phosphate buffer saline (PBS) and then
lysed for 5 min on ice in cell lysis buffer (25 mM Tris-HCl,
150 mM NaCl pH 7.6, supplemented with 1% Triton X-100, 1%
sodium deoxycholate and 0.1% SDS). Proteins were quantified by
using the Micro BCA Protein BSA Assay Kit (Fischer Scientific).
Signals were detected using the Western Lightning-ECL,
Enhanced Chemiluminescence Substrate (Perkin Elmer) according
to the manufacturer’s instructions. Signal detection was performed
by autoradiography and quantified with the ImageQuant LAS
4000 (GE Healthcare), using the ImageQuant LAS 4000 Control
Software for analysis.
Immunofluorescence staining
Cells were grown on glass coverslips, washed once with PBS and
fixed by incubation for 30 min with 4% paraformaldehyde in 0.1
M sodium phosphate buffer (pH 7.2) at room temperature. The
coverslips were rinsed three times with PBS for 5 min. The fixed
cells were then permeabilized with PBS containing 0.5% Triton
X-100 for 5 min and washed three times with PBS. Next, the fixed
cells were incubated for at least 60 min with a blocking solution
containing 0.1% Triton X-100 (Sigma-Aldrich), 1% BSA (Roche
Applied Science), and 5% normal goat serum (Life Technologies)
in PBS. After blocking, the cells were incubated overnight at 4uC
with primary antibodies diluted in the previously described
blocking solution. The cells were then washed again three times,
followed by incubation with the Alexa 488- or Alexa 568-
conjugated secondary antibodies (1:500, Life Technologies) for 1 h
at room temperature in the dark.
Immunostaining was detected through an inverted Leica SP5
spectral microscope with a 636 oil immersion lens at room
temperature. Data were therefore collected using the LAS 6000
AF software and finally processed in Adobe Photoshop 7.0 (Adobe
systems). Colocalization was quantified using the colocalization
plugin of ImageJ. The channel ratio was always set at 90%.
Real-time quantitative PCR
PCRs were performed for the MAN1B1 gene (GenBank
NM_016219.4) and the house-keeping gene HPRT (Hypoxanthine
PhosphoRibosylTransferase, GenBank NM_000194), which was
used as an endogenous control for normalization. PCR primers
were designed using Primer 3 software. All the primers were
synthesized by Integrated DNA Technologies. PCR primers used
are the followings: MAN1B1 (59-CTGTGGATCCCCGCCCG-
GAA-39 and 59-TCAGATGCACTGGTGTGCCCTGT-39) and
HPRT (59-GCCAGACTTTGTTGGATTTG-39 and 59-CTCT-
CATCTTAGGCTTTGTAT TTTG-39). PCRs (20 ml) were
performed using 26 LightCycler 480 SYBR Green I Master
(Roche Applied Science) with 2 ml of a 1:5 cDNA dilution and
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300 nM final concentration of each primer. Data were analysed
using the LightCycler 480 Software (Roche Applied Science). The
comparative threshold cycle method described by Livak and
Schmittgen was used to quantify the results [23]. In addition, serial
dilutions were used to create standard curves for relative
quantification, and the expression of the MAN1B1 transcript was
normalized to HPRT expression.
Metabolic labelling
Fibroblasts (86106 cells per labelling) were grown overnight in a
175 cm2 tissue culture flask. After 24 h, cells were preincubated
for 45 min in 0.5 mM glucose and then pulse-radiolabelled for 2 h
with 150 mCi of 2-[H3]-mannose (16 Ci.mmol21, Amersham
Biosciences) at the same glucose concentration. For chase
experiments, the radioactive culture medium was replaced by a
medium containing 5 mM glucose and 5 mM mannose. After
metabolic labelling or chase period, cells were scraped with 1.1 ml
MeOH/H2O (8:3) followed by the addition of 1.2 ml CHCl3.
Sequential extraction of oligosaccharide material was performed
as previously described [24].
Analysis of oligosaccharide material by HPLC
Glycoproteins fraction obtained at the end of the sequential
extraction were digested overnight at room temperature with
trypsin (1 mg.ml21; Sigma-Aldrich) in 0.1 M ammonium bicar-
bonate buffer, pH 7.9. The resulting glycopeptides were treated
with 0.5 U PNGase F (Roche Applied Science) in 50 mM
phosphate buffer, pH 7.2 for 4 h to release the oligosaccharides
from the peptides. They were subsequently desalted on Bio-Gel P2
columns and eluted with 5% acetic acid.
The oligosaccharides were afterwards separated by HPLC on
an amino derivated Asahipak NH2P-50 column (25064.6 mm;
Asahi) applying a gradient of acetonitrile/H2O ranging from
70:30 over 50:50 over 90 min at a flow rate of 1 ml per min.
Oligosaccharides were identified on the basis of their retention
time, compared to standard glycans, as previously described [24].
Elution of the labeled oligosaccharides was monitored by
continuous b-counting with a flo-one b detector (Packard).
Calculation peak counts
HPLC chromatograms were analysed using the ProFSA
software (Perkin Elmer). To compare the percentage of specific
oligomannoside structures, a fixed amount (50,000 dpm) of
radioactivity was injected into HPLC. The counts in each peak
were calculated on the basis of the peak area and normalized
against the total number of counts in the injected samples.
Moreover, the differences in the number of mannose residues
between the different oligomannoside structures were taken into
account. Hence, the radioactivity associated to the Man5 species
was multiplied by 9/5 to be comparable to the radioactivity
associated to the Man9 species.
Supporting Information
Figure S1 MAN1B1 mutations detected in the cohort. Chro-
matograms of patients P1, P2, P3, P4.1, P4.2 and P5 respectively
(A–F). Left panel: maternal allele. Right panel: paternal allele.
Upper sequence: wild type allele in a control. Bottom sequence:
mutant allele in the patient. The base pair of interest is marked
with *. Heterozygous variants are annotated as ‘N’. Concerning
panel B: note the presence of the benign variant
c.176A.G;p.N59S (#) both in the control as in patient P2. (G)
Chromatograms of patient P6 on genomic DNA (upper panel) and
cDNA (bottom panel). Left panel: maternal allele, showing a 4 bp
deletion within intron 9, leading to skipping of exon 9. Right
panel: de novo deletion of 6.453 bp on the paternal allele,
displaying the intronic boundary. Exonic base pairs are displayed
in capitals. Intronic base pairs are displayed in small cases. Please
note, this file is 41.7MB.
(EPS)
Figure S2 Conservation of amino acid residue across species
displayed for the described missense mutations p.S409P and
p.R334C, respectively.
(EPS)
Figure S3 Predicted identity and relative amounts of glycans
released from total serum N-glycoproteins. Abbreviations and
symbols: n.d., not detected; closed square, N-acetylglucosamine;
closed circle, mannose; open circle, galactose; closed diamond,
sialic acid; and closed triangle, fucose.
(EPS)
Figure S4 Intracellular distribution of MAN1B1 in control and
MAN1B1-deficient fibroblasts. Fibroblasts were double-labelled
with antibodies against MAN1B1 (green) and the Golgi marker
giantin (red), then fixed and processed for confocal laser scanning
microscopy. Images were collected under identical settings. Scale
bar represents 25 mm. Please note, this file is 49.8MB.
(EPS)
Figure S5 HPLC analysis of N-linked oligosaccharides from
control and patient’s fibroblasts. (A) Protein N-linked oligosaccha-
rides of MAN1B1-deficient individuals (P1, P3, P5) were separated
by HPLC after the pulse period (left panels) and 2 hours of chase
(right panels). Symbols: M8, M9 indicate oligosaccharide species
with 8 or 9 mannose residues and possessing two GlcNAc resides
at their reducing ends. G1M9 indicates oligosaccharide species
with 9 mannose and 1 Glc residues and possessing two GlcNAc
residues at their reducing ends. (B) Relative peak areas of M8
(black), M9 (red) and G1M9 (blue) were quantified. Values are
depicted as percentages of total peak areas. The depicted values
are the mean 6 SEM of independent experiments.
(EPS)
Table S1 CZE profile of serum transferrin. Distribution of the
transferrin isoforms in both control and MAN1B1-deficient
individuals. 3, 4, 5, and 6 respectively indicate trisialo-,
tetrasialo-, pentasialo-, and hexasialotransferrin isoforms. Values
are depicted as percentages of total transferrin.
(DOCX)
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